» Articles » PMID: 35402215

Bone Metastasis From Gastric Adenocarcinoma-What Are the Risk Factors and Associated Survival? A Large Comprehensive Population-Based Cohort Study

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Apr 11
PMID 35402215
Authors
Affiliations
Soon will be listed here.
Abstract

Background: While bone metastasis is not common in gastric adenocarcinoma (GaC), it can have important impacts on prognosis. This large cohort study aimed at exploring factors associated with bone metastasis in GaC and investigating the time-dependent cumulative mortalities and prognostic factors in GaC patients with bone metastasis at the population level.

Methods: Data on patients with GaC diagnosed in 2010-2016 were retrieved from a large population-based database. We explored factors associated with bone metastasis using the multivariable-adjusted logistic model. We then calculated the time-dependent cancer-specific mortalities in GaC patients with bone metastasis using the cumulative incidence function and compared mortalities across subgroups using Gray's test. We further assessed factors associated with mortality using the multivariable-adjusted Fine-Gray subdistribution hazard model.

Results: Together 11,072 eligible patients with metastatic GaC were enrolled, which comprised 1,511 (14%) people with bone metastasis and 9,561 (86%) with other metastasis, encompassing 6,999 person-years of follow-up. Bone metastasis was more frequently detected in 2014 or later, in younger patients, in patients with gastric cardia cancers, in people with signet-ring cell carcinoma, and in those with poorly differentiated/undifferentiated cancers; it was less commonly observed in black patients. Bone metastasis was associated with more frequent brain and lung metastases. The median survival of patients with bone metastasis was 4 months; the 6-month and 3-year cancer-specific cumulative mortalities were 56% and 85%, respectively. In patients receiving chemotherapy, American Indians/Alaskan Natives, patients with gastric antrum/pylorus cancers, and those with positive lymph nodes had higher mortality risks, while those undergoing resection had lower mortality hazards.

Conclusion: In GaC patients, bone metastasis was associated with various clinicopathologic factors including age, ethnicity, tumor location, histology, differentiation, and metastasis to other sites. Patients with bone metastasis had poor prognosis which was associated with ethnicity, tumor location, lymph node involvement, and treatment. Our findings provide important hints for tailed patient management and for further mechanistic investigations.

Citing Articles

Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives.

Luo D, Liu Y, Lu Z, Huang L Mol Med. 2025; 31(1):52.

PMID: 39923010 PMC: 11806620. DOI: 10.1186/s10020-025-01075-y.


Metastatic bone lesion type in gastric cancer patients: imaging findings of case reports.

Porta-Vilaro M, Soler-Perromat J, Larque A, Bartolome-Solanas A, Isern-Kebschull J, Garcia-Diez A Quant Imaging Med Surg. 2024; 14(11):7872-7880.

PMID: 39544462 PMC: 11558497. DOI: 10.21037/qims-24-425.


Genomic alterations of cerebrospinal fluid cell-free DNA in leptomeningeal metastases of gastric cancer.

Chen X, Bai K, Zhang Y, Xu Y, Huo Y, Wang S J Transl Med. 2023; 21(1):296.

PMID: 37131253 PMC: 10155444. DOI: 10.1186/s12967-023-04077-8.


Continuous care needs in patients with cancer receiving chemotherapy during the recent omicron wave of COVID-19 in Shanghai: A qualitative study.

Zhang J, Wang C, Huang L, Zhang J Front Psychol. 2023; 13:1067238.

PMID: 36687977 PMC: 9845893. DOI: 10.3389/fpsyg.2022.1067238.


Tumor Microenvironment, Clinical Features, and Advances in Therapy for Bone Metastasis in Gastric Cancer.

Sun P, Antwi S, Sartorius K, Zheng X, Li X Cancers (Basel). 2022; 14(19).

PMID: 36230816 PMC: 9563035. DOI: 10.3390/cancers14194888.


References
1.
Boku N, Ohtsu A, Nagashima F, Sano Y, Muto M, Fujii T . Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with bone metastasis. Gastric Cancer. 2002; 3(1):19-23. DOI: 10.1007/pl00011684. View

2.
Anagnostopoulos G, Sakorafas G, Kostopoulos P, Margantinis G, Tsiakos S, Pavlakis G . Early (mucosal) gastric cancer with synchronous osteosclerotic bone metastases: a case report. Eur J Cancer Care (Engl). 2009; 19(4):554-7. DOI: 10.1111/j.1365-2354.2007.00847.x. View

3.
Du J, Wei J, Yang Y, Su S, Shao J, Chen F . Disappearance of bone metastases in chemotherapy-resistant gastric cancer treated with antigen peptide-pulsed dendritic cell-activated cytotoxic T lymphocyte immunotherapy: A case report. Oncol Lett. 2018; 16(1):875-881. PMC: 6019880. DOI: 10.3892/ol.2018.8781. View

4.
Hess K . Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med. 1995; 14(15):1707-23. DOI: 10.1002/sim.4780141510. View

5.
Wen L, Li Y, Zhang J, Zhou C, Yang H, Chen X . Clinical analysis of bone metastasis of gastric cancer: incidence, clinicopathological features and survival. Future Oncol. 2019; 15(19):2241-2249. DOI: 10.2217/fon-2019-0039. View